By: Printed:



+F/GA:1652

Docket No.: PF-0148-2 DIV

Response Under 37 C.F.R. 1.116 - Expedited Pr cedure

**Examining Group 1652** 

hat secretify that this correspondence is being deposited with the mitted States Postal Service as first class mail in an envelope
fiited States Postal Service as first class mail in an envelope
ddressed to: Commissioner for Patents, Washington, D.C. 20231
A. I

Corres. and Mail

RECEIVED

SEP 07 20000

**TECH CENTER** 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Hawkins et al.

Title:

**HUMAN PYROPHOSPHATASE** 

Serial No.:

09/415,540

Filing Date:

8-Oct-99

Examiner:

Slobodyansky, E.

Group Art Unit: 1652

Box AF

Commissioner for Patents Washington, D.C. 20231

Sir:

Transmitted herewith are the following for the above-identified application:

- 1. Return Receipt Postcard; and
- 2. Response to Final Office Action (4 pp., in duplicate).

The fee has been calculated as shown below.

Claims	Claims Äfter Amendment		Claims Previously Paid For		Present Extra		Than Entity Fee	Additional: Fee(s)
Total Claims	6		20	=	0	\$18		\$0
Indep. Claims	2		- 3 -	-= "	O 	\$78-		\$0
First Presentation of Multiple Dependent Claim +\$260								\$0

TOTAL No additional fee is required. Please charge Deposit Account No. 09-0108 the amount of

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Peng Ben Wang, J.D.

Reg. No. 41,420

Direct Dial Telephone: (650) 621 -7574

3160 Porter Drive Palo Alto, California 94304 Phone: (650) 855-0555 Fax: (650) 849-8886



Docket No.: PF-0148-2 DIV

<u>Response Under 37 C.F.R. 1.116 - Expedited Procedure</u>

<u>Examining Group 1652</u>

I hereby certify that the posterior pondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231

on August 31, 2000 By:

Printed:

Nancy L. Glyng

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Hawkins et al.

Title:

**HUMAN PYROPHOSPHATASE** 

Serial No.:

09/415,540

Filing Date:

8-Oct-99

Examiner:

Slobodyansky, E.

Group Art Unit:

1652

Box AF

Commissioner for Patents Washington, D.C. 20231

**RESPONSE TO OFFICE ACTION** 

#13E 0

Sir:

In response to the Office Action dated May 31, 2000 (Final Office Action, Paper Number 12), Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

## IN THE CLAIMS

Please amend claim 19 as indicated below. For the Examiner's convenience, the non-amended pending claims are also listed below.

- 18. (Reiterated) The method of claim 20, wherein before hybridization, the target polynucleotide is amplified by the polymerase chain reaction.
  - 19. (Twice amended) An isolated polynucleotide selected from the group consisting of:
  - a) a polynucleotide sequence of SEQ ID NO:2,